Gland Pharma and Neuland Laboratories Announce Strategic Partnership for Sterile API Manufacturing Expansion

Gland Pharma and Neuland Laboratories Announce Strategic Partnership for Sterile API Manufacturing Expansion​

Gland Pharma Limited and Neuland Laboratories Limited have announced a long-term strategic CDMO partnership aimed at expanding sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities. This collaboration establishes a dedicated platform to meet the growing worldwide demand for complex sterile APIs, particularly those used in microparticle depot products.

Under the new partnership, Gland Pharma will establish a specialized sterile manufacturing suite at its JNPC facility in Visakhapatnam. This expansion is designed to support Neuland Laboratories as it addresses the increasing need for these critical compounds. The facility will be constructed and operated according to cGMP, USFDA, and EU standards, built upon Gland Pharma’s proven aseptic manufacturing expertise.

The collaboration integrates the complementary strengths of both organizations. Neuland brings its deep expertise in Complex API development and manufacturing, covering areas such as complex chemistry and process development for global innovator and generic pharmaceutical companies. Gland Pharma contributes its global sterile manufacturing expertise and strong regulatory compliance track record. Together, they will offer an integrated CDMO solution that encompasses the development, scale-up, regulatory support, and commercial manufacturing of sterile APIs.

The dedicated suite is designed to add approximately 1400 kg of annual capacity, ensuring flexibility across multiple sterile products while supporting future growth for both companies. This partnership is expected to significantly enhance global supply resilience by combining Neuland’s development and regulatory knowledge with Gland Pharma’s specialized manufacturing capabilities.

Commenting on the partnership, Mr. Srinivas Sadu, Executive Chairman of Gland Pharma Limited, stated that the strategic alliance expands the company's capabilities in sterile API manufacturing. He noted that by leveraging the complementary strengths of both organizations, they will provide a robust and scalable CDMO solution backed by world-class quality and compliance standards for sustainable growth.

Mr. Saharsh Davuluri, CEO & MD of Neuland Laboratories Limited, shared his views on the market trend, noting that demand for sterile APIs continues to rise as pharmaceutical companies advance increasingly complex injectable therapies. He added that through this partnership, they are combining Neuland's expertise in complex APIs with Gland's proven sterile manufacturing capabilities to create a differentiated platform, strengthening their commitment to delivering quality and supply assurance to global clients.

***
About Gland Pharma Limited: Established in 1978 in Hyderabad, Gland Pharma has evolved from a contract manufacturer of small-volume liquid parenteral products into one of the largest injectable-focused companies globally. Operating under a B2B model, it services over 60 countries and specializes in various injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

About Neuland Laboratories Limited: Neuland is a specialist API CDMO partner serving big pharma and biotech clients globally by providing world-class process development and commercial supply services for complex molecules and New Chemical Entities. The company operates three US FDA and EU GMP-compliant facilities in India and offers more than 100 APIs across multiple therapeutic areas.

GLAND Stock Price Movement​

Shares of Gland Pharma Limited slipped today, shedding 1.20% in the closed market to settle at ₹2545.1. The stock traded a total volume of 299,935 shares during the session.